JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 71 (final count)
- Started
- May 18, 2023
- Main results expected
- Jan 31, 2027
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants with Adverse events (AEs) by Severity
Measured over: Up to 2 years 3 months
Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Measured over: Up to Cycle 1 (Day 1 through Day 28)
Phase 2: Objective Response Rate
Measured over: Up to 2 years 3 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05908734 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC